{"id":"nimotuzumab-h-r3","safety":{"commonSideEffects":[{"rate":null,"effect":"Acneiform rash"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nimotuzumab binds to EGFR on cancer cells, preventing ligand-induced activation and downstream signaling that drives cell growth and division. Unlike some other anti-EGFR antibodies, it has a lower binding affinity that may reduce toxicity while maintaining anti-tumor activity. This mechanism is particularly relevant in cancers with EGFR overexpression.","oneSentence":"Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:08.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Head and neck squamous cell carcinoma"},{"name":"Non-small cell lung cancer"},{"name":"Colorectal cancer"}]},"trialDetails":[{"nctId":"NCT06879691","phase":"PHASE4","title":"A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2021-05-15","conditions":"Head and Neck Cancer","enrollment":171},{"nctId":"NCT06781073","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2017-07-06","conditions":"Cervical Squamous Cell Carcinoma, Persistent","enrollment":118},{"nctId":"NCT06429904","phase":"PHASE2","title":"Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-15","conditions":"Locally Advanced Pancreatic Cancer","enrollment":31},{"nctId":"NCT06422156","phase":"PHASE2","title":"SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-06-01","conditions":"Advanced Pancreatic Cancer","enrollment":73},{"nctId":"NCT06413017","phase":"PHASE2","title":"Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-08-31","conditions":"HCC","enrollment":30},{"nctId":"NCT06409429","phase":"PHASE2, PHASE3","title":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":146},{"nctId":"NCT06405685","phase":"PHASE2","title":"Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-27","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT03025958","phase":"PHASE2","title":"Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2017-03-13","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT02947386","phase":"PHASE1","title":"Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-06-29","conditions":"EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT04532229","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2021-04-03","conditions":"Diffuse Intrinsic Pontine Glioma","enrollment":48},{"nctId":"NCT00702481","phase":"PHASE2","title":"Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2008-04-28","conditions":"Head and Neck Cancer","enrollment":32},{"nctId":"NCT05717790","phase":"NA","title":"Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Fourth Affiliated Hospital of Guangxi Medical University","startDate":"2022-12-01","conditions":"Nasopharyngeal Carcinoma by AJCC V8 Stage","enrollment":288},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT02272699","phase":"PHASE2, PHASE3","title":"Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2014-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02672241","phase":"PHASE2","title":"Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Childhood Brain Stem Neoplasm","enrollment":30},{"nctId":"NCT02083211","phase":"PHASE3","title":"Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"National Institute of Cancerología","startDate":"2010-07","conditions":"Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment","enrollment":168},{"nctId":"NCT02034968","phase":"PHASE2","title":"Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2014-02","conditions":"Stage IV Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02011594","phase":"PHASE2","title":"Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2014-01","conditions":"Stage IV Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT01498562","phase":"PHASE2","title":"Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2011-12","conditions":"Non Small Cell Lung Cancer (NSCLC)","enrollment":160},{"nctId":"NCT00910117","phase":"PHASE2","title":"Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-05","conditions":"Head and Neck Cancer","enrollment":40},{"nctId":"NCT00872482","phase":"PHASE2","title":"A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases","status":"TERMINATED","sponsor":"YM BioSciences","startDate":"2009-04","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT00369447","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"YM BioSciences","startDate":"2009-03","conditions":"Non-small-cell Lung Cancer","enrollment":52},{"nctId":"NCT00369252","phase":"PHASE1","title":"Phase I Study of Nimotuzumab in Solid Tumours","status":"COMPLETED","sponsor":"YM BioSciences","startDate":"2005-06","conditions":"Advanced and/or Metastatic Solid Tumours","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CIMAHOPE"],"phase":"phase_3","status":"active","brandName":"Nimotuzumab ( h-R3)","genericName":"Nimotuzumab ( h-R3)","companyName":"El Kendi Pharmaceuticals Manufacturing Company","companyId":"el-kendi-pharmaceuticals-manufacturing-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"Nimotuzumab is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation and survival. Used for Head and neck squamous cell carcinoma, Non-small cell lung cancer, Colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}